Track 01 of 9
Stroke & Cerebrovascular Disease
Thrombectomy, mobile stroke units and stroke prevention.
Acute stroke care has been redefined by tenecteplase displacing alteplase as the preferred thrombolytic, late-window thrombectomy out to 24 hours guided by perfusion imaging (DAWN, DEFUSE-3), and increasingly the treatment of medium and distal vessel occlusions. GCNN 2027 will examine direct-to-angio-suite workflows, mobile stroke units, and the expanding evidence for thrombectomy in large core infarcts (SELECT2, ANGEL-ASPECT). The track will also cover secondary prevention with factor XI inhibitors, PFO closure post-RoPE, and the persistent gap in primary prevention for cerebral small vessel disease.
Focus areas
- Tenecteplase vs alteplase: AcT, ATTEST-2, and dosing strategies
- Late-window and large-core thrombectomy: SELECT2, ANGEL-ASPECT
- Medium and distal vessel occlusion thrombectomy trials
- Mobile stroke units and direct-to-angio-suite workflows
- Factor XI inhibitors (asundexian, abelacimab) in secondary prevention
- Cerebral small vessel disease and vascular cognitive impairment
- Intracerebral hemorrhage: bundle care, minimally invasive evacuation